RESUMO
Gentamicin sulfate and betamethasone phosphate were combined in solution form for topical ophthalmic use in patients with chronic staphylococcal blepharoconjunctivitis. The study involved 79 patients and was a two-week double-blind placebo controlled trial comparing the combination with its individual components and placebo. Lid cultures showed that the combination and gentamicin were significantly superior to placebo or betamethasone in freeing the lids of staphylococcus. In addition, the patients treated with either the combination or betamethasone showed greater improvement in the total objective signs than those patients treated with either gentamicin or placebo at the first follow-up visit. No drug-related adverse reactions occurred in the combination treatment group.
Assuntos
Betametasona/análogos & derivados , Blefarite/tratamento farmacológico , Conjuntivite/tratamento farmacológico , Doenças Palpebrais/tratamento farmacológico , Gentamicinas/administração & dosagem , Administração Tópica , Adulto , Idoso , Betametasona/administração & dosagem , Doença Crônica , Ensaios Clínicos como Assunto , Método Duplo-Cego , Combinação de Medicamentos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Soluções OftálmicasRESUMO
Oxymetazoline (0.025%) ophthalmic solution, 2 drops 4-times daily, was compared with a placebo in the treatment of allergic and non-infectious conjunctivitis. In this 1 week, double-blind, multi-centre study, oxymetazoline proved significantly superior to the placebo (p < 0.001) in providing rapid and sustained clearing of inflamed conjunctiva. Overall, 84% of allergic patients treated with oxymetzoline were improved compared to 58% on placebo. Patients with non-infectious conjunctivitis exhibited a high degree of improvement (94%) compared to placebo (51%).
